Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

Characterization of organic anion transporter (OAT) 2 and OAT7 expression in human hepatocytes and liver tissue.

Vildhede A, Kimoto E, Rodrigues AD, Varma MVS.

Mol Pharm. 2018 Jun 15. doi: 10.1021/acs.molpharmaceut.8b00320. [Epub ahead of print]

PMID:
29906129
2.

Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.

Yamazaki S, Loi CM, Kimoto E, Costales C, Varma MV.

Drug Metab Dispos. 2018 May 8. pii: dmd.118.080424. doi: 10.1124/dmd.118.080424. [Epub ahead of print]

PMID:
29739809
3.

Comparison of Proteomic Quantification Approaches for Hepatic Drug Transporters: Multiplexed Global Quantitation Correlates with Targeted Proteomic Quantitation.

Vildhede A, Nguyen C, Erickson BK, Kunz RC, Jones R, Kimoto E, Bourbonais F, Rodrigues AD, Varma MVS.

Drug Metab Dispos. 2018 May;46(5):692-696. doi: 10.1124/dmd.117.079285. Epub 2018 Feb 8.

PMID:
29439128
4.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 2: Prospectively Predicting Systemic and Liver Exposure in Healthy Subjects.

Li R, Kimoto E, Niosi M, Tess DA, Lin J, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):357-366. doi: 10.1124/dmd.117.078808. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):484.

PMID:
29330219
5.

A Study on Pharmacokinetics of Bosentan with Systems Modeling, Part 1: Translating Systemic Plasma Concentration to Liver Exposure in Healthy Subjects.

Li R, Niosi M, Johnson N, Tess DA, Kimoto E, Lin J, Yang X, Riccardi KA, Ryu S, El-Kattan AF, Maurer TS, Tremaine LM, Di L.

Drug Metab Dispos. 2018 Apr;46(4):346-356. doi: 10.1124/dmd.117.078790. Epub 2018 Jan 12. Erratum in: Drug Metab Dispos. 2018 Apr;46(4):483.

PMID:
29330218
6.

Estimation of Circulating Drug Metabolite Exposure in Human Using In Vitro Data and Physiologically Based Pharmacokinetic Modeling: Example of a High Metabolite/Parent Drug Ratio.

Obach RS, Lin J, Kimoto E, Duvvuri S, Nicholas T, Kadar EP, Tremaine LM, Sawant-Basak A.

Drug Metab Dispos. 2018 Feb;46(2):89-99. doi: 10.1124/dmd.117.078279. Epub 2017 Nov 17.

PMID:
29150544
7.

Liver-Targeted Small-Molecule Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9 Synthesis.

McClure KF, Piotrowski DW, Petersen D, Wei L, Xiao J, Londregan AT, Kamlet AS, Dechert-Schmitt AM, Raymer B, Ruggeri RB, Canterbury D, Limberakis C, Liras S, DaSilva-Jardine P, Dullea RG, Loria PM, Reidich B, Salatto CT, Eng H, Kimoto E, Atkinson K, King-Ahmad A, Scott D, Beaumont K, Chabot JR, Bolt MW, Maresca K, Dahl K, Arakawa R, Takano A, Halldin C.

Angew Chem Int Ed Engl. 2017 Dec 18;56(51):16218-16222. doi: 10.1002/anie.201708744. Epub 2017 Nov 24.

PMID:
29073340
8.

In vitro studies with two human organic anion transporters: OAT2 and OAT7.

Mathialagan S, Costales C, Tylaska L, Kimoto E, Vildhede A, Johnson J, Johnson N, Sarashina T, Hashizume K, Isringhausen CD, Vermeer LMM, Wolff AR, Rodrigues AD.

Xenobiotica. 2017 Oct 13:1-13. doi: 10.1080/00498254.2017.1384595. [Epub ahead of print]

PMID:
28945155
9.

Hepatobiliary Clearance Prediction: Species Scaling From Monkey, Dog, and Rat, and In Vitro-In Vivo Extrapolation of Sandwich-Cultured Human Hepatocytes Using 17 Drugs.

Kimoto E, Bi YA, Kosa RE, Tremaine LM, Varma MVS.

J Pharm Sci. 2017 Sep;106(9):2795-2804. doi: 10.1016/j.xphs.2017.04.043. Epub 2017 Apr 27.

PMID:
28456723
10.

Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.

Nguyen HQ, Lin J, Kimoto E, Callegari E, Tse S, Obach RS.

J Pharm Sci. 2017 Sep;106(9):2758-2770. doi: 10.1016/j.xphs.2017.03.032. Epub 2017 Apr 12.

PMID:
28412400
11.

Erratum to: Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes.

Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, Tremaine LM, Varma MVS.

AAPS J. 2017 May;19(3):882. doi: 10.1208/s12248-017-0061-0. No abstract available.

PMID:
28233243
12.

Reliable Rate Measurements for Active and Passive Hepatic Uptake Using Plated Human Hepatocytes.

Bi YA, Scialis RJ, Lazzaro S, Mathialagan S, Kimoto E, Keefer J, Zhang H, Vildhede AM, Costales C, Rodrigues AD, Tremaine LM, Varma MVS.

AAPS J. 2017 May;19(3):787-796. doi: 10.1208/s12248-017-0051-2. Epub 2017 Feb 10. Erratum in: AAPS J. 2017 May;19(3):882.

PMID:
28188574
13.

Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast.

Varma MV, Kimoto E, Scialis R, Bi Y, Lin J, Eng H, Kalgutkar AS, El-Kattan AF, Rodrigues AD, Tremaine LM.

Clin Pharmacol Ther. 2017 Mar;101(3):406-415. doi: 10.1002/cpt.520. Epub 2016 Nov 18.

PMID:
27648490
14.

Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.

Nguyen HQ, Kimoto E, Callegari E, Obach RS.

Drug Metab Dispos. 2016 May;44(5):781-91. doi: 10.1124/dmd.115.068601. Epub 2016 Mar 8.

15.

Hepatic Disposition of Gemfibrozil and Its Major Metabolite Gemfibrozil 1-O-β-Glucuronide.

Kimoto E, Li R, Scialis RJ, Lai Y, Varma MV.

Mol Pharm. 2015 Nov 2;12(11):3943-52. doi: 10.1021/acs.molpharmaceut.5b00411. Epub 2015 Sep 30.

PMID:
26378985
16.

Quantitative Rationalization of Gemfibrozil Drug Interactions: Consideration of Transporters-Enzyme Interplay and the Role of Circulating Metabolite Gemfibrozil 1-O-β-Glucuronide.

Varma MV, Lin J, Bi YA, Kimoto E, Rodrigues AD.

Drug Metab Dispos. 2015 Jul;43(7):1108-18. doi: 10.1124/dmd.115.064303. Epub 2015 May 4.

17.
18.

Physiologically based pharmacokinetic prediction of telmisartan in human.

Li R, Ghosh A, Maurer TS, Kimoto E, Barton HA.

Drug Metab Dispos. 2014 Oct;42(10):1646-55. doi: 10.1124/dmd.114.058461. Epub 2014 Aug 4.

19.

Kidney function, cholesterol absorption and remnant lipoprotein accumulation in patients with diabetes mellitus.

Sonoda M, Shoji T, Kimoto E, Okute Y, Shima H, Naganuma T, Motoyama K, Morioka T, Mori K, Fukumoto S, Shioi A, Koyama H, Emoto M, Inaba M.

J Atheroscler Thromb. 2014;21(4):346-54. Epub 2013 Dec 10.

20.

Quantitative assessment of the contribution of sodium-dependent taurocholate co-transporting polypeptide (NTCP) to the hepatic uptake of rosuvastatin, pitavastatin and fluvastatin.

Bi YA, Qiu X, Rotter CJ, Kimoto E, Piotrowski M, Varma MV, Ei-Kattan AF, Lai Y.

Biopharm Drug Dispos. 2013 Nov;34(8):452-61. doi: 10.1002/bdd.1861. Epub 2013 Oct 3.

PMID:
23996477
21.

Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide.

Varma MV, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, Kumar V.

Pharm Res. 2013 Apr;30(4):1188-99. doi: 10.1007/s11095-012-0956-5. Epub 2013 Jan 10.

PMID:
23307347
22.

Characterization of organic anion transporting polypeptide (OATP) expression and its functional contribution to the uptake of substrates in human hepatocytes.

Kimoto E, Yoshida K, Balogh LM, Bi YA, Maeda K, El-Kattan A, Sugiyama Y, Lai Y.

Mol Pharm. 2012 Dec 3;9(12):3535-42. doi: 10.1021/mp300379q. Epub 2012 Nov 2.

PMID:
23082789
23.

Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

Karlgren M, Vildhede A, Norinder U, Wisniewski JR, Kimoto E, Lai Y, Haglund U, Artursson P.

J Med Chem. 2012 May 24;55(10):4740-63. doi: 10.1021/jm300212s. Epub 2012 May 15.

24.

Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.

Lai Y, Varma M, Feng B, Stephens JC, Kimoto E, El-Kattan A, Ichikawa K, Kikkawa H, Ono C, Suzuki A, Suzuki M, Yamamoto Y, Tremaine L.

Expert Opin Drug Metab Toxicol. 2012 Jun;8(6):723-43. doi: 10.1517/17425255.2012.678048. Epub 2012 Apr 18. Review.

PMID:
22509796
25.

In vitro evaluation of hepatic transporter-mediated clinical drug-drug interactions: hepatocyte model optimization and retrospective investigation.

Bi YA, Kimoto E, Sevidal S, Jones HM, Barton HA, Kempshall S, Whalen KM, Zhang H, Ji C, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Jun;40(6):1085-92. doi: 10.1124/dmd.111.043489. Epub 2012 Mar 1. Review.

26.

Mechanistic pharmacokinetic modeling for the prediction of transporter-mediated disposition in humans from sandwich culture human hepatocyte data.

Jones HM, Barton HA, Lai Y, Bi YA, Kimoto E, Kempshall S, Tate SC, El-Kattan A, Houston JB, Galetin A, Fenner KS.

Drug Metab Dispos. 2012 May;40(5):1007-17. doi: 10.1124/dmd.111.042994. Epub 2012 Feb 16.

27.

Antialbuminuric advantage of cilnidipine compared with L-type calcium channel blockers in type 2 diabetic patients with normoalbuminuria and microalbuminuria.

Fukumoto S, Ishimura E, Motoyama K, Morioka T, Kimoto E, Wakikawa K, Shoji S, Koyama H, Shoji T, Emoto M, Nishizawa Y, Inaba M; Cilnidipine vs L-type calcium channel blockers Evaluation of Antihypertensive Renoprotective Effects in Diabetic patients (CLEARED) Study Investigators.

Diabetes Res Clin Pract. 2012 Jul;97(1):91-8. Epub 2012 Feb 13.

PMID:
22336632
28.

Differential modulation of cytochrome P450 activity and the effect of 1-aminobenzotriazole on hepatic transport in sandwich-cultured human hepatocytes.

Kimoto E, Walsky R, Zhang H, Bi YA, Whalen KM, Yang YS, Linder C, Xiao Y, Iseki K, Fenner KS, El-Kattan AF, Lai Y.

Drug Metab Dispos. 2012 Feb;40(2):407-11. doi: 10.1124/dmd.111.039297. Epub 2011 Oct 26.

29.

Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology.

Maurer TS, Ghosh A, Haddish-Berhane N, Sawant-Basak A, Boustany-Kari CM, She L, Leininger MT, Zhu T, Tugnait M, Yang X, Kimoto E, Mascitti V, Robinson RP.

AAPS J. 2011 Dec;13(4):576-84. doi: 10.1208/s12248-011-9297-2. Epub 2011 Aug 26.

30.

Preclinical species and human disposition of PF-04971729, a selective inhibitor of the sodium-dependent glucose cotransporter 2 and clinical candidate for the treatment of type 2 diabetes mellitus.

Kalgutkar AS, Tugnait M, Zhu T, Kimoto E, Miao Z, Mascitti V, Yang X, Tan B, Walsky RL, Chupka J, Feng B, Robinson RP.

Drug Metab Dispos. 2011 Sep;39(9):1609-19. doi: 10.1124/dmd.111.040675. Epub 2011 Jun 20.

31.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Pfefferkorn JA, Litchfield J, Hutchings R, Cheng XM, Larsen SD, Auerbach B, Bush MR, Lee C, Erasga N, Bowles DM, Boyles DC, Lu G, Sekerke C, Askew V, Hanselman JC, Dillon L, Lin Z, Robertson A, Olsen K, Boustany C, Atkinson K, Goosen TC, Sahasrabudhe V, Chupka J, Duignan DB, Feng B, Scialis R, Kimoto E, Bi YA, Lai Y, El-Kattan A, Bakker-Arkema R, Barclay P, Kindt E, Le V, Mandema JW, Milad M, Tait BD, Kennedy R, Trivedi BK, Kowala M.

Bioorg Med Chem Lett. 2011 May 1;21(9):2725-31. doi: 10.1016/j.bmcl.2010.11.103. Epub 2010 Nov 26.

PMID:
21183342
32.

Characterization of digoxin uptake in sandwich-cultured human hepatocytes.

Kimoto E, Chupka J, Xiao Y, Bi YA, Duignan DB.

Drug Metab Dispos. 2011 Jan;39(1):47-53. doi: 10.1124/dmd.110.034298. Epub 2010 Oct 6.

33.

Brachial-ankle pulse wave velocity as an index of central arterial stiffness.

Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H, Emoto M, Nishizawa Y.

J Atheroscler Thromb. 2010 Jun 30;17(6):658-65. Epub 2010 May 13.

34.

Central versus peripheral arterial stiffness in association with coronary, cerebral and peripheral arterial disease.

Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H, Emoto M, Nishizawa Y.

Atherosclerosis. 2010 Aug;211(2):480-5. doi: 10.1016/j.atherosclerosis.2010.03.037. Epub 2010 Apr 9.

PMID:
20430390
35.

C-Aryl glycoside inhibitors of SGLT2: Exploration of sugar modifications including C-5 spirocyclization.

Robinson RP, Mascitti V, Boustany-Kari CM, Carr CL, Foley PM, Kimoto E, Leininger MT, Lowe A, Klenotic MK, Macdonald JI, Maguire RJ, Masterson VM, Maurer TS, Miao Z, Patel JD, Préville C, Reese MR, She L, Steppan CM, Thuma BA, Zhu T.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1569-72. doi: 10.1016/j.bmcl.2010.01.075. Epub 2010 Jan 21.

PMID:
20149653
36.

Plasma angiopoietin-like protein 3 (ANGPTL3) concentration is associated with uremic dyslipidemia.

Shoji T, Hatsuda S, Tsuchikura S, Kimoto E, Kakiya R, Tahara H, Koyama H, Emoto M, Tabata T, Nishizawa Y.

Atherosclerosis. 2009 Dec;207(2):579-84. doi: 10.1016/j.atherosclerosis.2009.05.023. Epub 2009 May 27.

PMID:
19540497
37.

Application of stable isotope methodology in the evaluation of the pharmacokinetics of (S,S)-3-[3-(methylsulfonyl)phenyl]-1-propylpiperidine hydrochloride in rats.

Yamazaki S, Toth LN, Kimoto E, Bower J, Skaptason J, Romero D, Heath TG.

Drug Metab Dispos. 2009 May;37(5):937-45. doi: 10.1124/dmd.108.025478. Epub 2009 Feb 23.

38.

Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis.

Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Kimoto E, Koyama H, Emoto M, Nishizawa Y.

Atherosclerosis. 2009 Feb;202(2):582-8. doi: 10.1016/j.atherosclerosis.2008.04.042. Epub 2008 May 1.

PMID:
18492490
39.

Efflux transport of N-monodesethylamiodarone by the human intestinal cell-line Caco-2 cells.

Kimoto E, Seki S, Itagaki S, Matsuura M, Kobayashi M, Hirano T, Goto Y, Tadano K, Iseki K.

Drug Metab Pharmacokinet. 2007 Aug;22(4):307-12.

40.

Association between plasma angiopoietin-like protein 3 and arterial wall thickness in healthy subjects.

Hatsuda S, Shoji T, Shinohara K, Kimoto E, Mori K, Fukumoto S, Koyama H, Emoto M, Nishizawa Y.

J Vasc Res. 2007;44(1):61-6. Epub 2006 Dec 21.

PMID:
17191020
41.

Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease.

Kimoto E, Shoji T, Shinohara K, Hatsuda S, Mori K, Fukumoto S, Koyama H, Emoto M, Okuno Y, Nishizawa Y.

J Am Soc Nephrol. 2006 Aug;17(8):2245-52. Epub 2006 Jul 12.

42.

Body fat mass and lean mass as predictors of survival in hemodialysis patients.

Kakiya R, Shoji T, Tsujimoto Y, Tatsumi N, Hatsuda S, Shinohara K, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y.

Kidney Int. 2006 Aug;70(3):549-56. Epub 2006 Jun 21.

43.

Regional arterial stiffness associated with ischemic heart disease in type 2 diabetes mellitus.

Hatsuda S, Shoji T, Shinohara K, Kimoto E, Mori K, Fukumoto S, Koyama H, Emoto M, Nishizawa Y.

J Atheroscler Thromb. 2006 Apr;13(2):114-21.

44.

Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus.

Shinohara K, Shoji T, Kimoto E, Yokoyama H, Fujiwara S, Hatsuda S, Maeno T, Shoji T, Fukumoto S, Emoto M, Koyama H, Nishizawa Y.

J Atheroscler Thromb. 2005;12(4):205-10.

45.

Altered relationship between body fat and plasma adiponectin in end-stage renal disease.

Shoji T, Shinohara K, Hatsuda S, Kimoto E, Fukumoto S, Emoto M, Tahara H, Koyama H, Ishimura E, Miki T, Tabata T, Nishizawa Y.

Metabolism. 2005 Mar;54(3):330-4.

PMID:
15736110
46.

Molecular forms of adiponectin in uraemic plasma.

Shoji T, Kimoto E, Shinohara K, Hatsuda S, Nishizawa Y.

Nephrol Dial Transplant. 2004 Jul;19(7):1937-8. No abstract available.

PMID:
15199210
47.

Arterial stiffness in predialysis patients with uremia.

Shinohara K, Shoji T, Tsujimoto Y, Kimoto E, Tahara H, Koyama H, Emoto M, Ishimura E, Miki T, Tabata T, Nishizawa Y.

Kidney Int. 2004 Mar;65(3):936-43.

48.

Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population.

Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y.

Nephrol Dial Transplant. 2004 Jan;19(1):179-84.

PMID:
14671054
49.

Pulse wave velocity in lower-limb arteries among diabetic patients with peripheral arterial disease.

Yokoyama H, Shoji T, Kimoto E, Shinohara K, Tanaka S, Koyama H, Emoto M, Nishizawa Y.

J Atheroscler Thromb. 2003;10(4):253-8.

50.

The association of antibodies against oxidized low-density lipoprotein with atherosclerosis in hemodialysis patients.

Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T, Tsujimoto Y, Tabata T, Nishizawa Y.

Kidney Int Suppl. 2003 May;(84):S128-30.

PMID:
12694327

Supplemental Content

Loading ...
Support Center